Listed

Radiopharm Theranostics Ltd: Form 20-F for the period ended Jun 30, 2025

Filed with the SEC on Sep 18, 2025 and accepted by EDGAR at Sep 17, 2025, 20:00 ET.

Share

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2025-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue12 months2024-07-01 to 2025-06-30$3.6mifrs-full:Revenue
Cost of revenue12 months2024-07-01 to 2025-06-30$3.6mifrs-full:CostOfSales
Gross profit12 months2024-07-01 to 2025-06-30$39.3kifrs-full:GrossProfit
Operating income12 months2024-07-01 to 2025-06-30−$38.2mifrs-full:ProfitLossFromOperatingActivities
Income tax12 months2024-07-01 to 2025-06-30$103.3kifrs-full:IncomeTaxExpenseContinuingOperations
Net income12 months2024-07-01 to 2025-06-30−$38.3mifrs-full:ProfitLoss
Diluted EPS12 months2024-07-01 to 2025-06-30−$1.76ifrs-full:DilutedEarningsLossPerShare
Basic EPS12 months2024-07-01 to 2025-06-30−$1.76ifrs-full:BasicEarningsLossPerShare
Operating cash flow12 months2024-07-01 to 2025-06-30−$36.6mifrs-full:CashFlowsFromUsedInOperatingActivities
Cash and equivalentsAt period end2025-06-30$29.1mifrs-full:CashAndCashEquivalents
Current assetsAt period end2025-06-30$39.9mifrs-full:CurrentAssets
Total assetsAt period end2025-06-30$86.5mifrs-full:Assets
Current liabilitiesAt period end2025-06-30$14.9mifrs-full:CurrentLiabilities
Total liabilitiesAt period end2025-06-30$43.6mifrs-full:Liabilities
Shareholders' equityAt period end2025-06-30$42.9mifrs-full:Equity
Shares outstandingAt period end2025-06-302,364,949,502 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001213900-25-088699. Last ingested by Listed: Nov 4, 2026, 08:00 ET. Listed shows no prices and gives no investment advice.